EP1660880A1 - Dispositif et procede d'evaluation quantitative des polypeptides contenus dans un echantillon de liquide corporel et marqueur permettant de detecter des etats pathologiques - Google Patents

Dispositif et procede d'evaluation quantitative des polypeptides contenus dans un echantillon de liquide corporel et marqueur permettant de detecter des etats pathologiques

Info

Publication number
EP1660880A1
EP1660880A1 EP04764788A EP04764788A EP1660880A1 EP 1660880 A1 EP1660880 A1 EP 1660880A1 EP 04764788 A EP04764788 A EP 04764788A EP 04764788 A EP04764788 A EP 04764788A EP 1660880 A1 EP1660880 A1 EP 1660880A1
Authority
EP
European Patent Office
Prior art keywords
polypeptides
combination
polypeptide
diabetes
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04764788A
Other languages
German (de)
English (en)
Inventor
Harald Mischak
Stefan Wittke
Thorsten Kaiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mosaiques Diagnostics and Therapeutics AG
Original Assignee
Mosaiques Diagnostics and Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mosaiques Diagnostics and Therapeutics AG filed Critical Mosaiques Diagnostics and Therapeutics AG
Publication of EP1660880A1 publication Critical patent/EP1660880A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Definitions

  • the invention relates to devices and methods for the quantitative evaluation of the polypeptides contained in a body fluid sample and comparison with reference values stored in a database, as well as markers for the detection of pathological conditions.
  • DE 100 21 737 C2 discloses a method and a device for the qualitative and / or quantitative determination of a protein and / or polypeptide pattern of a liquid sample. Proteins and / or polypeptides of a liquid sample are separated by capillary electrophoresis, then directly ionized and transferred online via an interface to a mass spectrometer coupled to them for detection.
  • Diabetes is often a precursor to diabetic nephropathy, which can develop over years and decades.
  • the nephropathy in diabetes goes through several Stadiums.
  • An early diagnosis of diabetic nephropathy is difficult with the currently available means, only with great effort and only at a relatively late point in time.
  • Timely diagnosis and consistent treatment of manifest nephropathy would not only prevent or delay the need for dialysis, but would also reduce the high cardiovascular risk of the patient with diabetes.
  • polypeptide patterns of a liquid sample e.g. Urine
  • a liquid sample e.g. Urine
  • Further studies show that the diagnosis of diseases other than the aforementioned diabetes and diabetic nephropathy is also possible via polypeptide patterns.
  • the invention is based on the object of specifying, in a device and a method for the quantitative evaluation of the polypeptides contained in a body fluid sample and comparison with reference values stored in a database, a definition of the polypeptides suitable for computer-controlled storage and evaluation.
  • This task is performed in a device for the quantitative evaluation of the polypeptides contained in a body fluid sample and comparison with reference values stored in a database, characterized in that the reference values are stored as data records of state-relevant polypeptides, each of which contains at least one indication of the probability of occurrence and / or the concentration of the polypeptides for a pathological condition in samples from healthy and sick test subjects, and in a method for the quantitative evaluation of the polypeptides contained in a body fluid sample and comparison with reference values stored in a database, characterized in that the reference values as data sets of condition-relevant polypeptides can be used for the comparison by giving an indication of the probability of the occurrence and / or concentration of the polypeptides in the body fluid sample with the Specification of at least one reference value about the probability of the occurrence and / or the concentration of the polypeptides for a pathological condition in samples from healthy and sick test subjects is compared.
  • the invention is also based on the object of specifying a marker for recognizing pathological conditions via a definition of the polypeptides contained which is suitable for storage and evaluation.
  • This task is identified in a marker for the detection of pathological conditions, characterized by a plurality of condition-relevant polypeptides, each of which is linked to an indication of the probability of the occurrence and / or the concentration of the polypeptide for a pathological condition in samples from healthy and sick test subjects , solved.
  • polypeptides are evaluated, the concentration of which changes significantly in the body fluid in a pathological state compared to a normal state.
  • concentration of which changes significantly in the body fluid in a pathological state compared to a normal state can be determined in preliminary studies with a large number of subjects.
  • Each polypeptide is linked to information which, for a pathological condition, includes information about the probability of occurrence or concentration in a healthy and in a sick subject.
  • polypeptides can be defined by specifying their associated mass and their associated capillary electrophoresis retention time.
  • the capillary electrophoresis retention time can be determined, for example, by capillary electrophoresis using a 90 cm long glass capillary with an inner diameter (ID) of 75 ⁇ m and an outer diameter (OD) of 360 ⁇ m at a voltage of 30 kV, using as solvent for the sample 30% methanol, 0.5% formic acid in water is used.
  • ID inner diameter
  • OD outer diameter
  • condition-relevant polypeptides were summarized in a database, which were determined and verified on the basis of urine samples from a large number of test subjects. Individual polypeptides, a combination of polypeptides or all polypeptides can be compared here.
  • polypeptides serving as markers can potentially also be therapeutic targets. This makes it possible to develop therapeutics that have these polypeptides either as a basis or as a target structure.
  • the occurrence and / or the concentration of the polypeptides are changed in each case by supplementation and / or antibodies in the body in such a way that their concentration in the examined body fluid again assumes normal values.
  • Fig. 2 graphical representations of polypeptide patterns and their relationship.
  • the presence and the concentration of a large number of polypeptides in the urine are analyzed. This is currently done by means of capillary electrophoresis coupled to a mass spectrometer (CE-MS), but can also be done with other methods.
  • CE-MS mass spectrometer
  • Fig. Lb shows the image of the "Raw data", from which relevant signals, referred to in FIG. 1c as “recognized signals”, are first filtered out using a filter and evaluation software, and then a polypeptide pattern, referred to in FIG. 1d as "polypeptide pattern", is calculated the polypeptides are annotated / identified by their mass and retention time in the CE and their concentration is calculated from the amplitude of the signal.
  • the data forming the polypeptide pattern are stored in a database.
  • the information required for unambiguous identification is stored in a separate data record for each relevant polypeptide.
  • Fig. Le symbolically shows a screen representation of several data records.
  • a typical polypeptide pattern of healthy kidneys was created from the database comparison of over 50 measurements. The same technology was used to measure urine samples from over 200 Type I and Type II diabetes patients. These patients represent groups of different stages of kidney disease, from completely normal to values of over 3 g protein / day in the urine.
  • a group-specific polypeptide pattern is developed from the collected polypeptide patterns of an investigation group.
  • the polypeptide patterns obtained in this way show typical deviations from the normal samples, ie changes in individual polypeptides.
  • graphical representations of the group-specific polypeptide patterns according to the table in FIG. 2 are shown.
  • polypeptide patterns of the group K0, PO, Pl, P2 are shown in Fig. 2a, 2b, 2c, 2d.
  • a synthetic overall picture is assembled from the polypeptide patterns of groups K0, PO, Pl, P2 and this is used as a marker profile to create a polypeptide pattern according to FIG. 2e.
  • the changes in the polypeptide pattern are partly due to the underlying disease diabetes and can therefore be found evenly in all diabetics, partly due to or also the cause of the beginning / progressing nephropathy. These polypeptides can thus be used as markers for the diagnosis of diabetes or diabetic nephropathy.
  • polypeptides present there are then searched for in the examined patient samples, after which their presence or absence is used for the diagnosis, as shown in FIG. 2f.
  • the following table summarizes the particularly relevant marker polypeptides found in the context of the detection of diabetic nephropathy.
  • the polypeptides mentioned here serve to identify the disease at an early stage and can be used individually, in part or in full combination.
  • the list contains 380 polypeptides, defined by their mass and their retention time in capillary electrophoresis. Sequence numbers 1 to 157 form the marker peptides used for the diagnosis "diabetes”. Sequence numbers 158 to 380 contain the marker peptides used for the diagnosis "kidney damage”. Within these two groups, the polypeptides are initially sorted according to whether they are a “Positive”, ie polypeptide that occurs more frequently in the event of illness, or a “negative”. The polypeptides are then sorted in ascending order according to their mass.
  • the device according to the invention or the method according to the invention is additionally characterized in that the polypeptides are defined by stating their associated mass and their associated capillary electrophoresis retention time, as can be determined in the case of capillary electrophoresis coupled to a mass spectrometer.
  • the database for the diagnosis "diabetes" comprises at least one, a sub-combination or all data records of the polypeptides No. 1 to No. 157 of the table above.
  • the database for the diagnosis "kidney damage" at least one, a sub-combination or all data sets of polypeptides No. 158 to 380 of the table above.
  • the marker according to the invention is additionally characterized in that the polypeptides are defined by stating their associated mass and their associated capillary electrophoresis retention time, as can be determined in the case of capillary electrophoresis coupled to a mass spectrometer.
  • the marker is characterized in that for the diagnosis “diabetes” at least one polypeptide, a sub-combination of the polypeptides or all polypeptides from No. 1 to 157 of the table above or for the diagnosis “kidney damage” at least one polypeptide, a sub-combination of the polypeptides or all polypeptides Nos. 158 to 380 of the table above are included.
  • particularly preferred polypeptide combinations can be used for the device, the method or the marker.
  • Polypeptides No. 32 (A), 1 (B), 48 (C), 2 (D), 44 (E), 22 (F), 9 (G), 23 (H) are "positive” polypeptides as diabetes. and 20 (I) and their combinations, in particular as indicated below, are preferred.
  • Polypeptides No. 123 (A), 153 (B), 155 (C), 105 (D), 150 (E), 121 (F), 157 (G), 92 (H) are "negative” polypeptides as diabetes. and 69 (I) and their combinations, in particular as indicated below, are preferred.
  • Polypeptides No. 225 (A), 208 (B), 164 (C), 166 (D), 171 (E), 204 (F), 206 (G), 182 (H) are “positive” polypeptides as nephropathy. and 210 (I) and their combinations, in particular as indicated below, are preferred.
  • Polypeptides No. 262 (A), 260 (B), 306 (C), 358 (D), 279 (E), 318 (F), 305 (G), 261 (H) are "nephropathy” negative and 278 (I) and combinations, particularly as indicated below, are preferred.
  • two of the preferred polypeptides A, B, C, D, E, F, G, H and I mentioned above are identified as “negative” as diabetes, “positive” as diabetes, and “negative” as nephropathy or "positive” polypeptides used as nephropathy.
  • these are the combinations of the polypeptides:
  • a and B A and C, A and D, A and E, A and F, A and G, A and H, A and I, - B and C, B and D, B and E, B and F, B and G, B and H, B and I, - C and D, C and E, C and F, C and G, C and H, C and I, - D and E, D and F, D and G, D and H, D and I, - E and F, E and G, E and H, E and I, - F and G, F and H, F and I, - G and H, G and I or - H and l.
  • three of the preferred polypeptides A, B, C, D, E, F, G, H and I mentioned above are "negative” as diabetes, "positive” as diabetes, “negative” as nephropathy or "positive” polypeptides used as nephropathy.
  • these are the combinations of the polypeptides:
  • four of the preferred polypeptides A, B, C, D, E, F, G, H and I mentioned above are "negative” as diabetes, "positive” as diabetes, “negative” as nephropathy or "positive” polypeptides used as nephropathy.
  • five of the preferred polypeptides A, B, C, D, E, F, G, H and I mentioned above are "negative” as diabetes, "positive” as diabetes, “negative” as nephropathy or "positive” polypeptides used as nephropathy.
  • these are the combinations of the polypeptides:
  • six of the preferred polypeptides A, B, C, D, E, F, G, H and I mentioned above are "negative” as diabetes, "positive” as diabetes, “negative” as nephropathy or "positive” polypeptides used as nephropathy.
  • these are the combinations of the polypeptides:
  • seven of the preferred polypeptides A, B, C, D, E, F, G, H and I mentioned above are "negative” as diabetes, "positive” as diabetes, “negative” as nephropathy or "positive” polypeptides used as nephropathy.
  • these are the combinations of the polypeptides:
  • eight of the preferred polypeptides A, B, C, D, E, F, G, H and I mentioned above are "negative” as diabetes, "positive” as diabetes, “negative” as nephropathy or "positive” polypeptides used as nephropathy.
  • these are the combinations of the polypeptides:
  • all nine of the preferred polypeptides A, B, C, D, E, F, G, H and I mentioned above are "negative” as diabetes, "positive” as diabetes, “negative” as nephropathy or "positive” polypeptides used as nephropathy.
  • these are the combinations of the polypeptides:

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Dispositifs et procédés d'évaluation quantitative des polypeptides contenus dans un échantillon de liquide corporel et marqueur permettant de détecter des états pathologiques. Les polypeptides sont comparés à des valeurs de référence mises en mémoire dans une banque de données. Ces valeurs de référence sont mises en mémoire en tant que groupes de données concernant des polypeptides pertinents pour un état, ces groupes de données comprenant au moins une indication sur la probabilité de l'apparition et / ou de la concentration des polypeptides pour un état pathologique dans des échantillons provenant de personnes testées malades et en bonne santé.
EP04764788A 2003-09-06 2004-09-03 Dispositif et procede d'evaluation quantitative des polypeptides contenus dans un echantillon de liquide corporel et marqueur permettant de detecter des etats pathologiques Withdrawn EP1660880A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10341193A DE10341193A1 (de) 2003-09-06 2003-09-06 Vorrichtung und Verfahren zur quantitativen Auswertung der in einer Körperflüssigkeitsprobe enthaltenden Polypeptide sowie Marker zur Erkennung von pathologischen Zuständen
PCT/EP2004/009833 WO2005024409A1 (fr) 2003-09-06 2004-09-03 Dispositif et procede d'evaluation quantitative des polypeptides contenus dans un echantillon de liquide corporel et marqueur permettant de detecter des etats pathologiques

Publications (1)

Publication Number Publication Date
EP1660880A1 true EP1660880A1 (fr) 2006-05-31

Family

ID=34223428

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04764788A Withdrawn EP1660880A1 (fr) 2003-09-06 2004-09-03 Dispositif et procede d'evaluation quantitative des polypeptides contenus dans un echantillon de liquide corporel et marqueur permettant de detecter des etats pathologiques

Country Status (11)

Country Link
US (1) US20070082402A1 (fr)
EP (1) EP1660880A1 (fr)
JP (1) JP4765078B2 (fr)
KR (1) KR20060132558A (fr)
CN (1) CN1846133A (fr)
AU (1) AU2004270861B9 (fr)
BR (1) BRPI0413332A (fr)
CA (1) CA2537588A1 (fr)
DE (1) DE10341193A1 (fr)
RU (1) RU2425374C2 (fr)
WO (1) WO2005024409A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
EP1869473A2 (fr) * 2005-04-06 2007-12-26 mosaiques diagnostics and therapeutics AG Marqueur de polypeptide pour le diagnostic d'alzheimer
JP2008537112A (ja) * 2005-04-07 2008-09-11 モザイクヴェス ディアグノシュティクス アンド テラポイティクス アクチェン ゲゼルシャフト 前立腺がんの診断のためのポリペプチドマーカー
US20100200401A1 (en) * 2005-06-29 2010-08-12 Harald Mischak Polypeptide Markers for the Early Recognition of the Rejection of Transplanted Kidneys
ATE519116T1 (de) * 2007-03-07 2011-08-15 Mosaiques Diagnostics & Therap Verfahren zur normierung der konzentration von analyten in einer urinprobe
EP1972940A1 (fr) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Procédé et marqueur destinés à diagnostiquer des maladies des reins
AU2008309605A1 (en) * 2007-10-09 2009-04-16 Mosaiques Diagnostics And Therapeutics Ag Polypeptide marker for the diagnosis of prostate cancer
EP2051078A1 (fr) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Procédé et marqueur destinés à diagnostiquer le diabète sucré
EP2255203A2 (fr) * 2008-03-19 2010-12-01 Mosaiques Diagnostics And Therapeutics AG Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux
EP2338054A1 (fr) * 2008-09-17 2011-06-29 Mosaiques Diagnostics And Therapeutics AG Carcinome à cellules rénales
CN117233413A (zh) 2019-08-05 2023-12-15 禧尔公司 用于样品制备、数据生成和蛋白质冠分析的系统和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001033B1 (ru) * 1996-08-13 2000-08-28 Биовизион Гмбх Унд Ко.Кг Способ определения состояния организма посредством измерения пептидов
DE19702774C2 (de) * 1997-01-27 2002-04-18 Pe Diagnostik Gmbh Verfahren zur Ermittlung von Daten für eine Wissensbank und ihre Verwendung bei der Analyse von Gleichgewichtssituationen der in Wechselwirkung befindlichen Mineralien und Spurenelemente in Körperflüssigkeiten
DE19919982C2 (de) * 1999-04-30 2001-06-28 Pe Diagnostik Gmbh Verfahren zur Ermittlung osteoporotischer Prozesse
DE10021597A1 (de) * 2000-05-04 2001-11-15 Forschungszentrum Juelich Gmbh Verfahren zur Optimierung der Parameter eines Trennungsverfahrens für Stoffgemische
DE10021737C2 (de) * 2000-05-04 2002-10-17 Hermann Haller Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
US20020087273A1 (en) * 2001-01-04 2002-07-04 Anderson Norman G. Reference database
WO2003019193A1 (fr) * 2001-08-30 2003-03-06 Ciphergen Biosystems, Inc. Procede de diagnostic du syndrome nephrotique
CN1659431A (zh) * 2002-02-19 2005-08-24 新加坡基因组研究院 用于等电聚焦的设备

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005024409A1 *

Also Published As

Publication number Publication date
JP4765078B2 (ja) 2011-09-07
JP2007504466A (ja) 2007-03-01
US20070082402A1 (en) 2007-04-12
CN1846133A (zh) 2006-10-11
KR20060132558A (ko) 2006-12-21
WO2005024409A1 (fr) 2005-03-17
BRPI0413332A (pt) 2006-10-10
DE10341193A1 (de) 2005-03-31
RU2006111095A (ru) 2006-08-10
CA2537588A1 (fr) 2005-03-17
RU2425374C2 (ru) 2011-07-27
AU2004270861B2 (en) 2010-11-18
AU2004270861B9 (en) 2011-01-27
AU2004270861A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
EP0922226B1 (fr) Procede de determination de l'etat d'un organisme par mesure des peptides
DE102015212953A1 (de) Künstliche neuronale Netze zur Klassifizierung von medizinischen Bilddatensätzen
EP2648122A1 (fr) Procédé de chargement de données d'images médicales ainsi que le dispositif de réalisation du procédé
EP1660880A1 (fr) Dispositif et procede d'evaluation quantitative des polypeptides contenus dans un echantillon de liquide corporel et marqueur permettant de detecter des etats pathologiques
DE102007018034A1 (de) Automatische Bildanalyse und Quantifizierung für Fluoreszenz-In Situ-Hybridisierung
DE102022112136A1 (de) Medizinisches bildanalysegerät, verfahren und medizinisches bild, visualisierungsgerät und verfahren
WO2008107476A1 (fr) Procédé pour normaliser la concentration d'analytes dans un échantillon d'urine
DE202022103523U1 (de) Ein Klassifizierungssystem für diabetische Fußgeschwüre
WO2004068130A2 (fr) Procede et dispositif pour la determination qualitative et/ou quantitative d'un motif proteique et/ou peptidique d'un echantillon de liquide preleve sur le corps d'un homme ou d'un animal
EP1381846B1 (fr) Procede d'analyse d'un echantillon biologique
DE4331018C2 (de) Verfahren zur Bewertung von Blutproben
DE102006035617A1 (de) Automatische Bestimmung von Tumorlast
EP0922266B1 (fr) Procede de determination d'anomalies significatives de la croissance cellulaire
DE102019218597B4 (de) Verfahren zum Erstellen eines Befundes zur Funktionalität eines anorexigenen Signalwegs für einen Patienten
EP1687756B9 (fr) Procede pour classifier des valeurs de mesures dans des analyses medicales et biochimiques
EP3422002B1 (fr) Procédé de dépistage destiné au diagnostic d'un néoplasme hématologique
WO2004021245A2 (fr) Procede, dispositif, programme informatique comprenant un systeme de code de programmation et produit de programme informatique pour analyser des activites neuronales dans des zones neuronales
EP3809115A1 (fr) Procédé de classification d'agrégations de thrombocytes
WO2023057334A1 (fr) Procédé et système mis en œuvre par ordinateur pour diagnostiquer des maladies affectant les caractéristiques morphologiques et la complexité cytoplasmique des cellules sanguines
DE102005062163A1 (de) Verfahren zur Identifizierung von prediktiven Biomarken aus Patientendaten
EP1682917B1 (fr) Procede de verification de la structure spatiale correcte de molecules par spectroscopie a resonance magnetique nucleaire
CN115064262A (zh) 一种基于长短时记忆的阿尔兹海默症病程预测方法
DE112021003974T5 (de) Prüfgerät
WO2021209093A1 (fr) Traitement de maladies inflammatoires non transmissibles au moyen d'une substance qui inhibe la transcription du gène cebpb ou la fonction de la protéine cebpb
DE2343529C3 (de) Einrichtung zur Erkennung von krebsverdächtigen zytologlschen Präparaten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR LT LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060406

Extension state: LT

Payment date: 20060406

Extension state: HR

Payment date: 20060406

17Q First examination report despatched

Effective date: 20070306

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160401